Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1160P - Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study

Date

10 Sep 2022

Session

Poster session 16

Topics

Cancer in Older Adults

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yoshihito Kogure

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

Y. Kogure1, A. Kada2, H. Hashimoto3, S. Atagi4, Y. Takiguchi5, H. Saka1, N. Ebi6, A. Inoue7, T. Kurata8, Y. Fujita9, Y. Nishii10, T. Shibayama11, H. Itani12, T. Endo13, N. Yamamoto14, A. Gemma15

Author affiliations

  • 1 Department Of Respiratory Medicine, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP
  • 2 Clinical Research Center, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP
  • 3 Core Laboratory, Nagoya City University Graduate School of Medical Sciences, 4678602 - Nagoya/JP
  • 4 Health Management Center, JCHO Yamatokoriyama Hospital, 639-1013 - Koriyama/JP
  • 5 Medical Oncology Department, Chiba University, School of Medicine, 260-8677 - Chiba/JP
  • 6 Department Of Respiratory Medicine, Fukuoka University Hospital, 8140180 - Fukuoka Johnan/JP
  • 7 Palliative Medicine Department, Tohoku University Hospital, 9808575 - Sendai/JP
  • 8 Department Of Thoracic Oncology, Kansai Medical University, 573-1010 - Hirakata/JP
  • 9 Respiratory Medicine Dept., Asahikawa Medical Center, 708644 - Asahikawa/JP
  • 10 Respiratory Center, Matsusaka MUnicipal Hospital, 515-8544 - Matsusaka/JP
  • 11 Department Of Respiratory Medicine, NHO Okayama Medical Center, Okayama/JP
  • 12 Department Of Respiratory Medicine, Ise Red Cross Hospital, 516-8512 - Ise/JP
  • 13 Division Of Respiratory Medicine, NHO Mito Medical Center, 311-3193 - Ibaraki/JP
  • 14 Internal Medicine Iii, Wakayama Medical University, 641-8509 - Wakayama/JP
  • 15 Department Of Pulmonary Medicine, Nippon Medical School Main Hospital, 113-8603 - Tokyo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1160P

Background

The CAPITAL study, a randomized phase III trial, was conducted to compare carboplatin and nab-paclitaxel (nab-P/C) with docetaxel (D) for treating elderly patients with squamous-cell lung cancer.

Methods

We performed a safety analysis for patients ≥75 and <75 years old from each treatment group, post-hoc analysis of the impact of second-line immune checkpoint inhibitors (ICI) on survival, and intra-cycle nab-paclitaxel skip status.

Results

The common adverse events (AEs) in the nab-P/C group were leucopenia, neutropenia, and anemia, while leucopenia, neutropenia, and febrile neutropenia were common in the D group. In the D group, there was a high frequency of AEs, particularly neutropenia for patients ≥75. In the nab-P/C group, the common AEs were anemia and thrombocytopenia for those patients. Thirty-eight percent (74/190) of the patients were transferred to the second-line ICI treatment, 36 and 38 patients from the nab-P/C and D groups, respectively. The overall survival of patients on ICI depended on their reason for discontinuing the first treatment. In both groups, improvement of overall survival was observed in patients with disease progression after first-line therapy. Median overall survival after discontinuation of nab-P/C was 321 d with ICI and 142 d without ICI; in the D group, it was 311 d with ICI and 256 d without ICI. However, no survival benefit was seen in patients who discontinued due to AEs. Their median overall survival after discontinuing nab-P/C was 224 d with ICI and 373 d without ICI; after discontinuing D, the median overall survival was 186.5 d with ICI and 154 d without ICI. In cycle one and two, 10%–30% of patients skipped taking nab-paclitaxel, and over 50% skipped taking it after cycle 3.

Conclusions

Nab-P/C improved overall survival more than D in elderly patients with advanced or recurrent squamous cell lung cancer. ICI treatment did not improve the overall survival of patients in both groups, who discontinued the first line treatment due to AEs. Nab-P/C did not show a significant increase in toxicity in patients over 75 y of age. Many patients skipped nab-paclitaxel within cycles.

Clinical trial identification

UMIN000019843; jRCTs041180110.

Editorial acknowledgement

Legal entity responsible for the study

NHO Nagoya Medical Center.

Funding

Taiho Pharmaceutical.

Disclosure

Y. Kogure: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Boehringer Ingelheim, Ono Pharmaceutical; Financial Interests, Institutional, Invited Speaker: MSD, Taiho Pharmaceutical. A. Kada: Financial Interests, Institutional, Funding: Taiho Pharmaceutical. S. Atagi: Financial Interests, Personal, Invited Speaker: Eli Lilly, AstraZeneca, Ono, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, Hisamitsu, MSD, Eli Lilly, Chugai, Kyowa Hakko Kirin, Merck, Novartis Pharma, Thermo Fisher Scientific; Non-Financial Interests, Personal, Other: Roche. Y. Takiguchi: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Pfizer, Bristol Meyers Squib, MSD, Daiichi Sankyo, Japan Eli Lilly, Boehringer Ingelheim, Kyowa-Kirin; Financial Interests, Personal, Research Grant: Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Bristol Meyers Squib, MSD, Merck, Japan Eli Lilly, Takeda, Boehringer Ingelheim, Daiichi Sankyo. H. Saka: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Boehringer, Boston Scientific, Covidien, Ono, Taiho, Ili Lilly, MSD, Becton Dickinson, Chugai, Amco, Kyowa Hakko Kirin, Kyorin, Pfizer, Novartis Pharma, Fuji Film TOyama; Financial Interests, Institutional, Funding: AstraZeneca, MSD, Ono, Ili Lilly, Bristol Meyers, Chugai, Beyer, Olympus, Boehringer, Novartis Pharma, Pfizer, Takeda, Otsuka, Harada, Nobeopharma, Celgene, Taisho Toyama. A. Inoue: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Eli Lilly, Boehringer Ingelheim, Chugai, Daiichi Sankyo, MSD, Ono. T. Kurata: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD, Eli Lilly, Chugai, Ono, Bristol Myers, Boehringer Ingelheim, Pfizer; Financial Interests, Personal, Principal Investigator: AstraZeneca, MSD, Ono, Eli Lilly, Takeda. Y. Fujita: Financial Interests, Personal, Invited Speaker: Lilly, Chugai Pharmaceutical, AstraZeneca, Taiho Pharmaceutical; Financial Interests, Institutional, Funding: Lilly, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical. Y. Nishii: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Novartis pharma, Boehringer Ingelheim, Bayer Yakuhin, Glaxo SmithKline. T. Shibayama: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Novartis International AG; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutica, Ono Pharmaceutical, Merck; Financial Interests, Personal, Expert Testimony: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim, Novartis International AG, Merck, bostonscientific.com, Pfizer, EP-CRSU Co., Ltd., Okayama University, National Hospital Organization Nagoya Medical Center, Shimane University, West Japan Oncology Group; Financial Interests, Institutional, Funding: Ono Pharmaceutical. H. Itani: Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, Chugai Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Bristol Myers, MSD; Financial Interests, Institutional, Funding: Chugai Pharmaceutical. N. Yamamoto: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Ono Pharmaceutical, Daiichi Sankyo, Thermo Fisher Scientific, Daiichi Sankyo, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer Ingelheim, Novartis, Pfizer, Bristol Myers Squibb, Nippon Kayaku, GlaxoSmithKline, Sanofi, Hisamitsu Pharmaceutical, Merk biopharma, Guardant Health Japan; Financial Interests, Institutional, Advisory Role: AstraZeneca, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, Nippon Kayaku, Life Technologies Japan, Amgen, Guardant Health Japan, Janssen Pharmaceutical; Financial Interests, Personal, Funding: Chugai Pharmaceutical, Boehringer Ingelheim, Tosoh Life Science Research Laboratory; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Otsuka Pharmaceutica, Chugai Pharmaceutical, Shionogi, Daiichi Sankyo, Eli Lilly Japan, Tsumura, Nippon Kayaku, Asahi Kasei Pharma, Janssen Pharmaceutical, Taiho Pharmaceutical, Sanofi, Amgen. A. Gemma: Financial Interests, Personal, Invited Speaker: Pfizer, Ono, Boehringer, Taiho, Kyowakirin, AstraZeneca, Chugai, Novartis, Bristol; Financial Interests, Personal, Advisory Board: MSD, Nihon Kayaku, Daiichi Sankyo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.